Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Latest News – 20 January 2026

Sustainability

Paul-Ehrlich-Institut Receives EMAS Certification

Medicinal Product Supply

Influenza Vaccine Efluelda Available in Germany with Italian Label

In Vitro Diagnostic Medical Devices

Paul-Ehrlich-Institut Designated as an EU Reference Laboratory for in Vitro Diagnostic Medical Devices for the Detection of Blood Grouping Markers

Pharmacovigilance

CAR T-Cell Therapy and Secondary Tumour Development – Coincidence or Connection?

Pandemic Preparedness

ZEPAI Welcomes HERA Delegation for Exchange on the Future of Pandemic Preparedness

#VaccineFacts

#VaccineFacts Continue Their Impact: The Paul-Ehrlich-Institut Provides Vaccine Information – Even Beyond the Digital Awareness Campaign

Medicine Safety

Pharmacovigilance Report on the Use of COVID-19 Vaccines – Status as of 31 December 2024

FAQ: What should be taken into account when using public data on reports of suspected adverse events?

Information on the Topic of Vaccination Damages

The Paul-Ehrlich-Institut is not responsible for processing applications for recognition of vaccine damages.

The Paul-Ehrlich-Institut does not have any information, figures/data on vaccine damage procedures.

Recognition procedures for vaccination damages in accordance with section 24 of the Social Code (Sozialgesetzbuch, SGB) XIV are handled exclusively by the Social Welfare Office in the federal state in whose territory the vaccination was carried out. Sections 4, 5 and 113 of the SGB XIV provide information on the competent authority, compensation for official measures and payment obligations.

Important Short Links for Your Research

Updated: 20.01.2026

top